Capital Bluecross vector-borne testing Coverage Update | OpenPayer
CurrentCapital BluecrossPolicy AHS - G2158
Testing for Vector-Borne Infections
Clinical coverage policy for laboratory testing of vector-borne infections (ticks, mosquitoes, fleas, mites) describing which diagnostic methods meet or do not meet coverage criteria for specific pathogens and clinical situations; applies to Capital Bluecross members in North Carolina.
Policy Summary
PayerCapital Bluecross
PolicyTesting for Vector-Borne Infections
Policy CodePolicy AHS - G2158
Change TypeNo material change indicated
Effective DateMar 1, 2026
Next Review DateN/A
Key ActionObtain and document appropriate acute and convalescent paired serology (minimum two weeks apart) or timely NAAT/microscopy based on pathogen and symptom timing to meet coverage criteria.
No material clinical or coverage changes in this revision.
>15distinct pathogen entries
NCapplicable state
Initial + confirmatorypaired serology recommended
84.2%BinaxNOW sensitivity
73
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
references
Coverage Criteria for Vector-Borne Infections
Babesiosis
Covered when testing method and clinical suspicion match the pathogen-specific criteria below:
Babesiosis: For individuals suspected of having babesiosis, Giemsa- or Wright-stain blood smear microscopy, NAAT/PCR for Babesia DNA, or IgG/IgM indirect immunofluorescence antibody (IFA) assay (initial and confirmatory testing a minimum of two weeks apart) MEET COVERAGE CRITERIA.
See guidance on paired serology for confirmation; most PCR assays detect B. microti (see IDSA/ASM).
Relapsing fever (HTRF, LBRF, STRF/TBRF)
Relapsing fever (Borrelia spp.): For suspected relapsing fever: HTRF (hard-tick relapsing fever) — serologic assays for Borrelia antibodies or NAAT for Borrelia miyamotoi; LBRF (louse-borne relapsing fever) — peripheral blood smear microscopy or NAAT for Borrelia recurrentis; STRF/TBRF (soft-tick/tick-borne relapsing fever) — dark-field microscopy, Wright- or Giemsa-stained blood smear microscopy, NAAT for Borrelia spp., or serologic assays MEET COVERAGE CRITERIA.
Culture for Borrelia DOES NOT MEET COVERAGE CRITERIA.
Chikungunya
Chikungunya: For suspected chikungunya, viral culture, NAAT on blood, or IFA IgM testing (acute and convalescent phases) MEET COVERAGE CRITERIA.
Use testing appropriate to timing of illness (acute vs convalescent).
Colorado tick fever (CTF)
Colorado tick fever (CTF): For suspected Colorado tick fever, NAAT testing or IFA for CTF-specific IgM antibodies MEET COVERAGE CRITERIA.
Order tests consistent with clinical presentation and specimen timing.
Dengue (DENV)
Dengue virus (DENV): For suspected dengue, NAAT (e.g., RT-PCR), IgM MAC-ELISA, NS1 ELISA, and confirmatory plaque-reduction neutralization test (PRNT) MEET COVERAGE CRITERIA; IgG ELISA or hemagglutination testing DOES NOT MEET COVERAGE CRITERIA for acute diagnosis.
Testing modality depends on timing: NAAT/NS1 preferred ≤7 days; IgM primary after >7 days (CDC guidance).
Ehrlichiosis and Anaplasmosis
Ehrlichiosis and Anaplasmosis: For suspected ehrlichiosis or anaplasmosis, NAAT/PCR of whole blood, IFA IgG serology (acute and convalescent paired sera for confirmation), or microscopy to detect intraleukocytic morulae MEET COVERAGE CRITERIA. IFA IgM or standard blood culture DOES NOT MEET COVERAGE CRITERIA.
Perform PCR within first week of illness when possible because doxycycline reduces PCR sensitivity; paired serology (2–4 weeks) for confirmation.
Malaria
Malaria: For suspected malaria, rapid immunochromatographic diagnostic tests (RDTs) or smear microscopy to diagnose malaria, speciate Plasmodium, identify life-cycle stage, and/or quantify parasitemia MEET COVERAGE CRITERIA; microscopy may be repeated up to three times within three days if initial microscopy is negative. NAAT/PCR to confirm Plasmodium species MEETS COVERAGE CRITERIA; IFA for Plasmodium antibodies DOES NOT MEET COVERAGE CRITERIA.<=3 repeats within 3 days
RDTs (e.g., BinaxNOW) are FDA-approved but have lower sensitivity in some settings and require confirmation by microscopy.
Rickettsial diseases
Rickettsial diseases: For suspected rickettsial disease, IFA IgG assay (acute and convalescent testing a minimum of two weeks apart) MEETS COVERAGE CRITERIA.
Standard blood culture, NAAT, or IFA IgM DOES NOT MEET COVERAGE CRITERIA for routine diagnosis; tissue biopsy PCR/immunohistochemistry may be used when available.
West Nile virus (WNV)
West Nile virus (WNV): For suspected WNV, IFA for WNV-specific IgG or IgM in serum or CSF and confirmatory PRNT MEET COVERAGE CRITERIA. Nucleic acid detection (NAAT/PCR) MEETS COVERAGE CRITERIA for immunocompromised individuals; NAAT DOES NOT MEET COVERAGE CRITERIA for immunocompetent individuals.
CSF IgM more sensitive than CSF PCR for neuroinvasive disease; interpret serology in context of possible persistent IgM and cross-reactivity.
Yellow fever (YFV)
Yellow fever virus (YFV): For suspected yellow fever, NAAT for YFV or serologic assays to detect virus-specific IgM and IgG, plus confirmatory PRNT MEET COVERAGE CRITERIA.
Use confirmatory PRNT where flavivirus cross-reactivity complicates interpretation.
Zika virus (ZIKV)
Zika virus (ZIKV): NAAT for Zika MEETS COVERAGE CRITERIA for: symptomatic pregnant individuals up to 12 weeks after symptom onset with relevant exposure history; symptomatic non-pregnant individuals who live in or traveled to areas with an active CDC Zika Travel Health Notice when tested ≤7 days after symptom onset; and specific pregnancy/infant indications (prenatal ultrasound findings, infants born to positive-tested gestational parents, infants with congenital signs). NAAT and IgM testing plus confirmatory PRNT MEET COVERAGE CRITERIA for these pregnancy/infant and travel-exposed scenarios. NAAT/IgM testing for symptomatic non-pregnant individuals without travel outside the U.S./territories DOES NOT MEET COVERAGE CRITERIA. Testing asymptomatic individuals during general exams DOES NOT MEET COVERAGE CRITERIA.symptom timing and exposure-based as specified (eg, ≤7 days for non-pregnant symptomatic travel-exposed; up to 12 weeks for pregnant symptomatic).
Repeat positive NAAT on newly extracted RNA to rule out false positives; confirm IgM positives with PRNT when definitive diagnosis needed.
Recommended diagnostic approach by pathogen group
Testing selection should match pathogen biology, specimen timing, and clinical context; methods have specific windows and sensitivity characteristics.
Rickettsial testing: Use PCR (including tissue PCR) or serology (IFA) with paired acute/convalescent sera; IFA/ELISA are often unreliable in the first 5–14 days and IgG is more specific than IgM; tissue biopsy PCR or immunohistochemistry can be used when available.timing: IgG/ELISA generally ≥10–14 days; IFA unreliable first 5 days
Whole-blood PCR sensitivity varies by species; tissue PCR may be more sensitive for some Rickettsia.
Ehrlichiosis/Anaplasmosis testing: Use NAAT/PCR, IFA serology, or peripheral blood smear for morulae detection; culture is rarely useful due to difficulty and prolonged incubation.PCR preferably within first week of illness
Testing recommendations for dengue and Zika according to clinical context and timing
Acute-phase dengue testing: Patients within 0–7 days after symptom onset: perform NAAT (eg RT-PCR) plus IgM antibody test OR NS1 ELISA plus IgM antibody test; serum preferred. A negative NAAT/NS1 does not rule out infection.time: <=7 days
CDC recommends these combinations for acute-phase diagnosis.
Convalescent-phase dengue testing: >7 days after symptom onset: IgM ELISA is the primary diagnostic test; NAAT/NS1 antigen tests are less sensitive after day 7.time: >7 days
CDC guidance for convalescent testing.
Zika testing — asymptomatic pregnant patients: Routine testing is not recommended for asymptomatic pregnant patients residing in the U.S./territories; NAAT may be considered up to 12 weeks after travel to an area with an active CDC Zika Travel Health Notice.
IDSA/ASM diagnostic procedures and specimens
IDSA/ASM recommended diagnostic procedures and optimum specimens for tickborne, protozoal, and arboviral infections
Relapsing fever borreliae: Primary test: Wright's, Giemsa, or Diff-Quik stains of peripheral thin and thick blood smears; optimum specimens: blood or bone marrow; NAAT and serology as adjunctive tests.
IDSA/ASM Table 50 guidance.
Borrelia miyamotoi: NAAT is the primary test for acute infection; serology (EIA for GlpQ) can detect antibodies; optimal specimen: serum or paired serum/CSF for neuroborreliosis.
IDSA/ASM recommendations.
Anaplasma/Ehrlichia: Primary test for acute infection: NAAT of whole blood; alternate early test: Wright/Giemsa stain of peripheral blood or buffy coat if experienced technologists available; serology (acute and convalescent IFA IgG) for retrospective diagnosis.
Specimen: whole blood for NAAT (IDSA/ASM).
Testing modality & timing criteria
Testing modality and timing recommendations from cited clinical guidance (CDC, ASM, AAP, IEC):
Arboviruses (e.g., WNV, Zika, dengue, chikungunya): For most arboviruses, serologic testing of serum and CSF is preferred to molecular testing because viremia typically peaks before symptom onset; CSF IgM detection is more sensitive than CSF PCR for WNV neuroinvasive disease. Repeat testing and paired sera to demonstrate seroconversion or a fourfold rise are recommended when initial tests are negative but suspicion remains.timing relative to symptom onset; repeat testing recommended
IEC/ASM/AAP guidance; cross-reactivity limits serologic specificity and PRNT may be needed.
Anaplasma/Ehrlichia: Perform PCR within the first week of illness since doxycycline rapidly decreases PCR sensitivity; serology requires paired acute and convalescent sera with a fourfold rise for confirmation; single mildly elevated IgG or IgM may be non-diagnostic.PCR within 1st week; paired sera 2–4 weeks apart for serology
AAP Redbook guidance.
The Policy lists specific laboratory methods that DO NOT MEET COVERAGE CRITERIA. Examples include: culture testing for Borrelia in relapsing fever (culture explicitly excluded), IgG ELISA or hemagglutination testing for dengue, IFA IgM or standard blood culture for ehrlichiosis/anaplasmosis, IFA for Plasmodium antibodies, and NAAT for West Nile virus in immunocompetent individuals. The document also states that testing asymptomatic individuals during a general exam without abnormal findings does not meet coverage criteria.
The Policy explains that culture has limited routine utility for many vector-borne pathogens because growth can be time‑intensive, may require higher biosafety level laboratories, and in some cases is less sensitive than NAAT or serology. For relapsing fever specifically, culture testing for Borrelia is called out as not meeting coverage criteria.
Rapid diagnostic tests have important limitations: the FDA‑cleared BinaxNOW malaria test is faster but has reported lower sensitivity (~84.2%) and may misclassify Plasmodium falciparum as non‑falciparum. RDTs cannot distinguish all Plasmodium species, may be less sensitive than expert microscopy or PCR, and a negative RDT does not rule out malaria.
Routine Zika testing is not recommended for asymptomatic non‑pregnant patients. For pregnant patients, routine testing is also generally not recommended in many contexts; NAAT may be considered up to 12 weeks after travel to an area with an active CDC Zika Travel Health Notice, and testing of symptomatic pregnant patients follows distinct timing and specimen guidance.
Serologic testing has limitations for acute diagnosis of some infections. The Policy notes that serology (including IFA) is not recommended for acute diagnosis of babesiosis because antibodies can persist and do not distinguish recent from past infection; likewise, serologic testing for early localized Lyme disease (erythema migrans) is not routinely recommended.
Because IgG antibodies can persist long term, IgG testing alone is not specific for recent dengue infection. The CDC guidance cited warns that IgG serology may reflect prior flavivirus exposure and is not recommended to diagnose acute dengue without demonstration of seroconversion or a fourfold rise between paired sera.
The reference list and bibliographic section provide supporting literature and guideline citations but do not themselves state coverage criteria or exclusions; they are included as evidence resources rather than policy decisions.
The Policy explicitly states that testing for the listed vector‑borne infections in asymptomatic individuals during a general examination without abnormal findings DOES NOT MEET COVERAGE CRITERIA and may be denied.
The document discourages standalone use of less‑sensitive assays without confirmation: rapid or less‑sensitive tests should be confirmed by a more sensitive/specific method (for example PCR, microscopy, or paired serology) when diagnostic accuracy will affect clinical management.
For asymptomatic non‑pregnant patients, the Policy follows guideline guidance that testing for dengue or Zika is not recommended. Testing should be driven by clinical presentation and epidemiologic exposure rather than routine screening of asymptomatic individuals.
A single mildly elevated IgG or IgM titer for Anaplasma or Ehrlichia is not diagnostic of acute infection. The Policy cites guidance that serologic confirmation requires paired acute and convalescent sera demonstrating a ≥fourfold rise, and single low‑level titers—particularly in high‑prevalence regions—may be non‑diagnostic.
Within the portion of the document cited, there are no explicit 'not medically necessary' statements beyond the denial risks and exclusions already described; the reference listings themselves do not contain additional not‑medically‑necessary rules.
Applicable Procedure and Test Codes
Mentioned diagnostic testsmixed
BinaxNOW
FDA-approved malaria rapid test (trade name referenced)
Applicable CPT/HCPCS/PLA Codesmixed
86280
Hemagglutination inhibition test (HAI)
86382
Neutralization test, viral
86619
Antibody; Borrelia (relapsing fever)
86666
Antibody; Ehrlichia
86750
Antibody; Plasmodium (malaria)
86753
Antibody; protozoa, not elsewhere specified
86757
Antibody; Rickettsia
86788
Antibody; West Nile virus, IgM
86789
Antibody; West Nile virus
86790
Antibody; virus, not elsewhere specified
1–10 of 25
1/3
Provider Actions, Documentation, and Billing Guidance
Prior Authorization
Prior authorization
Prior authorization — No specific prior authorization requirements are stated in this section. Verify member benefits and any plan-specific medical necessity or prior authorization rules at the time of the request; government policies (LCD/NCD) may supersede this policy.
Documentation Required
Rapid malaria testing considerations
Rapid malaria testing considerations — Rapid diagnostic tests (RDTs) such as the FDA‑approved BinaxNOW provide faster results and may be useful when microscopy is not immediately available. However, RDTs have lower sensitivity than expert microscopy or PCR, may fail to detect low parasitemia or certain Plasmodium species (including misclassifying P. falciparum), cannot quantify parasitemia, and may remain positive after treatment. When relying on lower‑sensitivity RDTs, document the rationale for use, follow positive or negative RDTs with confirmatory microscopy (and/or PCR when needed), and note test limitations in the medical record.
BinaxNOW sensitivity reported ~84% and may misclassify P. falciparum
RDTs should be followed by microscopy to confirm species and quantify parasitemia
Background and Epidemiology
Background: Arthropod vectors (ticks, mosquitoes, fleas, mites) transmit a range of pathogens — bacteria, protozoa, and viruses — that cause diseases including Zika, West Nile virus, chikungunya, dengue, yellow fever, malaria, babesiosis, rickettsial infections (including Rocky Mountain spotted fever), ehrlichiosis/anaplasmosis, and relapsing fevers. Diagnostic approaches vary by pathogen and include culture, microscopy, NAAT (PCR/RT‑PCR), and serologic assays such as IFA and ELISA.
Definitions and Acronyms
NAAT definition
DefinitionNucleic acid amplification testing (NAAT) — e.g., PCR, qPCR, RT-PCR — used for direct detection of pathogen DNA or RNA in clinical specimens.
Typical usePreferred for detection of acute infection when pathogen nucleic acid is present in blood, CSF, urine, or tissue; often used within early illness windows for arboviruses and tickborne pathogens.
LimitationsTurnaround time and specimen-dependent sensitivity can limit utility for immediate clinical management; PCR may be less sensitive for some Rickettsia in whole blood.
IFA definition
DefinitionIndirect immunofluorescence antibody assay (IFA) — a serologic assay that detects IgG and/or IgM antibodies by indirect immunofluorescence.
Clinical role
Policy Revision History
2018-09-25policy_published
Initial policy publication for Testing for Vector-Borne Infections (Policy AHS - G2158).
2026-03-01policy_reviewedLatest
Most recent policy review completed (last_review date updated).
Policy Summary
PayerCapital Bluecross
PolicyTesting for Vector-Borne Infections
Policy CodePolicy AHS - G2158
Change TypeNo material change indicated
Effective DateMar 1, 2026
Next Review DateN/A
Key ActionObtain and document appropriate acute and convalescent paired serology (minimum two weeks apart) or timely NAAT/microscopy based on pathogen and symptom timing to meet coverage criteria.
Use blood smear (Giemsa/Wright) during febrile episodes and NAAT on blood/CSF/tissue; seroconversion or GlpQ antibody testing can distinguish relapsing fever from Lyme borreliosis.
sample timing: during febrile episode for smears
Dark-field microscopy may be useful when available.
Babesiosis testing: Preferred: blood smear microscopy and PCR for Babesia DNA; serology is adjunctive and not ideal for acute diagnosis due to persistent antibodies post-recovery.incubation: 1–4 weeks post-tick (up to months after transfusion)
Most PCR assays primarily detect B. microti; consider reference lab testing for species identification.
Malaria testing: Microscopic thick and thin blood smears and antigen-based RDTs are common; NAAT/PCR is more sensitive and useful for speciation and low parasitemia and is used as reference standard in studies.repeat smears every 12–24 h up to 72 h if suspicion persists
RDTs have sensitivity limitations and positive/negative results require confirmation by microscopy.
Arboviral testing: Use IgM MAC-ELISA for symptomatic cases with confirmatory PRNT or PCR in select situations (immunocompromised, prior flavivirus exposure, blood donors); NAAT preferred early in illness when viremia is present but has a limited detection window.timing: serology often requires ≥10–14 days; PCR detects early infection
Cross-reactivity among flaviviruses is common; PRNT improves specificity but may be limited to reference labs.
pregnancy/asymptomatic
CDC guidance indicates routine testing is generally not recommended.
Zika testing — symptomatic pregnant patients: Collect specimens as soon as possible up to 12 weeks after symptom onset: perform dengue and Zika NAAT and IgM on serum and Zika NAAT on urine; repeat positive Zika NAAT on newly extracted RNA to exclude false positives; perform PRNT for discordant IgM results.pregnancy/symptomatic (<=12 weeks)
CDC recommends combined molecular and serologic testing with confirmatory PRNT when needed.
Zika testing — infants with possible congenital infection: Collect infant serum and urine as soon as possible after birth for Zika NAAT and IgM; test CSF if obtained. If infant IgM is non-negative and NAAT negative and maternal PRNT not done, perform PRNT on infant serum; consider repeat PRNT at >=18 months when indicated.neonate/congenital
CDC neonatal testing recommendations.
Symptomatic non-pregnant patients: If lived in or traveled to area with active CDC Zika Travel Health Notice: perform dengue and Zika NAAT on serum collected ≤7 days after symptom onset; if NAAT negative or >7 days, perform IgM testing and confirm positive IgM with PRNT when definitive diagnosis is needed.non-pregnant symptomatic
CDC guidance for symptomatic non-pregnant patients.
Rickettsia spp.: Serology (acute and convalescent IFA IgG) and NAAT; optimal specimens include serum and skin biopsy (eschar margin) or autopsy tissues for NAAT or immunohistochemistry.
IDSA/ASM notes tissue specimens may improve detection.
Babesia: Primary acute tests: Giemsa/Wright-stained thick and thin blood smears (Giemsa preferred) and NAAT for acute infection; serology (acute and convalescent IFA IgG) is not recommended for acute diagnosis; most PCR assays mainly detect B. microti.
IDSA/ASM and AAP Redbook references.
Malaria: STAT microscopic examination of Giemsa-stained thick and thin films; repeat every 12–24 h for up to 3 exams before ruling out; rapid antigen test followed by confirmatory blood films; PCR from reference labs can detect and speciate.
IDSA/ASM recommends microscopy as primary acute diagnostic.
Arboviruses (Dengue, WNV, Zika): Molecular assays preferred early but detection window is limited; serology (IgM/IgG) used for later diagnosis; cross-reactivity among flaviviruses is common—consider PRNT for confirmatory specificity.
IDSA/ASM and WHO recommendations.
Rickettsial infections (e.g., RMSF):
IFA to R. rickettsii antigen is the gold standard; both IgG and IgM rise around 7–10 days but confirmation requires a fourfold or greater rise in IgG between acute (first 1–2 weeks) and convalescent (2–4 weeks later) sera.
paired sera with fourfold IgG rise
AAP Redbook recommendations.
Babesiosis and Malaria: Microscopic identification on thick and thin blood films is the primary diagnostic method; repeat smears every 12–24 hours for up to 72 hours if suspicion remains. Antibody testing is generally not helpful for acute malaria but can assist in babesiosis when smears and travel history are inconclusive or parasitemia is very low; some rapid antigen tests are FDA-approved but require confirmation by microscopy.serial smears over 72 hours; consider PCR for Babesia when microscopy negative
Document reason for using RDT instead of immediate microscopy (e.g., no experienced microscopist available, need for rapid triage)
Denial Risk
Asymptomatic screening denial risk
Asymptomatic screening denial risk — Testing for babesiosis, chikungunya, Colorado Tick Fever (CTF), dengue (DENV), ehrlichiosis/anaplasmosis, malaria, rickettsial disease, tick‑borne relapsing fever (TBRF), West Nile virus (WNV), yellow fever virus (YFV), or Zika virus in asymptomatic individuals during a general exam without abnormal findings does NOT meet coverage criteria and may be denied. Order testing only when clinical signs, exposure history, or epidemiologic risk justify evaluation.
Asymptomatic testing during general exams without findings may be denied
Document symptoms, exposure, travel, or epidemiologic rationale when ordering tests
Note
Use of culture
Use of culture — Culture may be required for certain organisms but is often not appropriate as a routine diagnostic test for many vector‑borne pathogens because: growth depends on the organism, obligate intracellular pathogens (e.g., Rickettsia, Anaplasma) need specialized cell culture, culture can be less sensitive than NAAT or serology, may be time‑intensive when treatment is urgent, and may require high biosafety level facilities. Use culture selectively (e.g., public health or epidemiology) and document rationale when ordered.
Standard blood culture does NOT meet coverage criteria for many rickettsial and ehrlichial infections
Culture often reserved for research, epidemiology, or specialized reference laboratories
Document if specimens are being sent to high‑complexity or public health/reference labs
Documentation Required
Quality‑assured tests required
Quality‑assured tests required — Only use laboratory tests that have undergone independent, comprehensive assessment of quality, safety, and performance. Testing for arboviruses and other vector‑borne infections should be performed in appropriately equipped laboratories by trained personnel. When using proprietary or specialized assays, document laboratory name and assay used.
Prefer tests with independent validation and known performance characteristics
Send complex testing (e.g., PRNT, specialized NAATs) to public health or reference labs when indicated
Document assay type and laboratory in the medical record
Note
Conflict with government policy
Conflict with government policy — If there is a conflict between this policy and any applicable government policy (e.g., Medicare LCDs or NCDs, or state Medicaid rules), the relevant government policy supersedes this policy. Check current CMS and state Medicaid guidance when applicable.
Refer to CMS Medicare Coverage Database for Medicare LCD/NCD updates
Follow applicable state Medicaid policy if it differs from this document
Prior Authorization
No authorization or denial criteria are
No authorization or denial criteria are listed in this section — This section does not provide explicit authorization or formal denial criteria beyond the coverage indications/limitations elsewhere in the policy. Clinical documentation supporting medical necessity (symptoms, exposure, timing relative to illness, and specimen type) should accompany test orders.
Attach clinical notes documenting symptoms, exposure/travel history, and reason for testing
If coverage is uncertain, verify benefit rules and preauthorization requirements with the payer prior to testing
Documentation Required
Paired serology documentation
Paired serology documentation — For infections where serology is used (e.g., Babesia, rickettsial diseases, some arboviruses), obtain and document paired acute and convalescent sera taken 2–4 weeks apart (or per guideline‑specified intervals). A ≥4‑fold rise in IgG titer between acute and convalescent specimens is considered confirmatory evidence of recent infection; document titers, dates of collection, and laboratory methods.
Collect acute sample early (as soon as possible after symptom onset) and convalescent sample 2–4 weeks later (or per pathogen‑specific guidance)
Document exact specimen collection dates, titer values, and fourfold or greater rises when present
Note when paired sera were not obtained and the diagnostic implications
Documentation Required
Specimen timing and type
Specimen timing and type — Order specimen types and timing according to the pathogen and test modality: NAAT (PCR) or antigen testing is most useful early in illness (often within first 7–14 days); serology (IgM/IgG, IFA) may be insensitive early and requires convalescent samples for confirmation. Use whole blood, serum, plasma, urine, CSF, or tissue as guideline‑recommended for the specific pathogen and document specimen type and collection time relative to symptom onset.
Document days since symptom onset on the laboratory requisition
Use urine NAAT for Zika in addition to serum when recommended
For WNV in immunocompromised patients, consider nucleic acid detection per guidelines
Documentation Required
Specimen timing and results documentation
Specimen timing and results documentation — Record the date/time of specimen collection, the specimen type, assay performed, and exact results (including titers and numeric PCR results when available). For serologic testing, document whether a fourfold rise in antibody titer was observed; for PCR, document specimen timing relative to therapy (e.g., doxycycline can reduce PCR sensitivity for Anaplasma/Ehrlichia) and interpret negative PCR in that context.
Record if PCR was collected prior to initiation of antibiotics (particularly doxycycline)
Document negative PCR results with notation if obtained after antimicrobial therapy started
Retain paired maternal/infant sera when indicated for congenital infections
Note
Evidence‑based scientific references
This section lists evidence‑based scientific references — Follow cited guidelines and primary literature (CDC, WHO, IDSA, AAP/Red Book, and peer‑reviewed studies) for diagnostic algorithms, specimen handling, and interpretation. When clinical decisions deviate from guideline recommendations, document the clinical justification.
Key sources include CDC guidance on malaria, Zika, dengue, babesiosis, and RMSF; WHO interim guidance; IDSA/ASM recommendations; and AAP Red Book guidance
Document reference(s) used when ordering non‑routine or investigational tests
Note
Empiric therapy vs early serology
Empiric therapy vs early serology — For certain infections (e.g., RMSF, ehrlichiosis/anaplasmosis, babesiosis), consider initiating empiric antimicrobial therapy when clinical suspicion is high rather than awaiting early serologic results, since early IFA/IgM tests may be insensitive and delay in treatment can worsen outcomes. Document clinical rationale for empiric therapy and any impact on diagnostic testing (e.g., decreased PCR sensitivity after doxycycline).
Document clinical signs (fever, rash, travel/exposure) and rationale for empiric doxycycline when indicated (e.g., suspected RMSF)
Note that serology may be negative early and that paired serology or alternative diagnostics may be required for confirmation
Documentation Required
Timing requirement for PCR
Timing requirement for PCR — Order PCR/NAAT testing early in the course of illness when viral or bacterial nucleic acid is most likely detectable (examples: within first week for anaplasmosis/ehrlichiosis and many arboviral infections). For anaplasmosis and ehrlichiosis specifically, perform PCR within the first week because doxycycline rapidly reduces PCR sensitivity. For malaria, PCR is useful to confirm species after initial diagnosis but may not be timely for acute management.
Collect whole blood for Anaplasma/Ehrlichia PCR prior to starting doxycycline when possible
For CTF and some arboviruses, RT‑PCR is more sensitive early and recommended within the early window specified by guidelines
Document timing of PCR collection relative to symptom onset and antimicrobial therapy
Standard reference serologic method for many tickborne rickettsial infections and used in paired acute/convalescent testing to demonstrate seroconversion or a fourfold rise.
Timing/limitationsInsensitive during the first week of illness; IgG is more specific than IgM due to cross-reactivity and elevated titers alone are insufficient for diagnosis without paired sera showing a fourfold rise.
Spotted fever rickettsiosis definition
DefinitionSpotted fever rickettsiosis — a broad epidemiologic designation (since 2010) that groups Rocky Mountain spotted fever (RMSF) with related rickettsial diseases (spotted fever group).
Clinical featuresTypical symptoms include fever, headache, and rash (rash appears in most patients by days 3–5); can be severe if untreated but amenable to timely antimicrobial therapy.
Diagnostic notesDefinitive culture is generally not possible in standard blood culture; diagnosis relies on skin biopsy PCR/immunohistochemistry or serology (IFA paired testing).
Neuroinvasive West Nile virus definition
DefinitionNeuroinvasive West Nile virus — WNV infection involving meningitis, encephalitis, or acute flaccid paralysis.
EpidemiologyRepresents the majority of reported symptomatic WNV hospitalizations; in 2023, 95% of domestic arbovirus cases were WNV and 68% of WNV cases were neuroinvasive.
DiagnosisCSF and serum IgM MAC-ELISA are commonly used for symptomatic neuroinvasive disease; CSF IgM is more sensitive than CSF PCR; confirmatory PRNT may be used in select situations.
Paired serology / fourfold rise definition
DefinitionPaired serology/fourfold rise — comparing acute and convalescent serum samples (typically collected 2–4 weeks apart; sometimes 2–10 weeks) where a ≥4-fold rise in antibody titer confirms recent/acute infection.
ApplicationRecommended for tickborne rickettsial diseases, babesiosis, and other infections where single elevated titers are insufficient to confirm acute infection.
DocumentationReport specimen collection timing and demonstrate the titer change; a fourfold rise equals a change of two dilutions (e.g., 1:64 to 1:256).
Rapid Diagnostic Test (RDT) / BinaxNOW definition
DefinitionRapid diagnostic test (RDT) — immunochromatographic antigen-detection assays (e.g., BinaxNOW) that provide results in ~2–15 minutes, commonly used for malaria antigen detection.
Use and approvalBinaxNOW Malaria test is FDA-approved for hospital and commercial laboratory use but not for clinician offices or patients.
LimitationsRDTs cannot distinguish all Plasmodium species, may be less sensitive than expert microscopy or PCR, cannot quantify parasitemia, and can remain positive after clearance; negative RDT does not rule out malaria.
PRNT definition
DefinitionPlaque reduction neutralization test (PRNT) — the reference-standard serologic assay that measures virus-specific neutralizing antibodies and improves specificity for arbovirus serology.
RoleUsed to confirm flavivirus infections (e.g., dengue, Zika, West Nile) when cross-reactivity among commercial serologic assays limits specificity.
AvailabilityComplex to perform and typically available only at select public health and CDC laboratories.
NAAT (RT-PCR) definition
DefinitionNAAT (RT-PCR) — reverse-transcription PCR and other nucleic acid amplification tests for detection of RNA viruses (e.g., Zika, dengue) and other pathogens by amplifying target nucleic acid sequences.
Specimen typesValidated specimen types include serum, plasma, CSF, urine, whole blood, or tissue depending on the pathogen and assay; specimen choice affects sensitivity.
TimingMost molecular assays are preferred early in illness (e.g., dengue and Zika within ~0–7 days of symptom onset) when viremia or antigenemia is present.
Seroconversion / fourfold rise
DefinitionSeroconversion / fourfold rise — demonstration of acute infection by seroconversion (negative to positive) or a ≥4-fold rise in antibody titer between paired acute and convalescent sera collected weeks apart.
RecommendationFor many arboviral and rickettsial infections, paired sera and documentation of seroconversion or a fourfold rise are recommended when initial tests are negative but clinical suspicion remains.
Interpretation caveatIgM or IgG antibodies may persist for months; single elevated titers may not indicate recent infection without paired testing showing the required rise.
LDT (Laboratory-Developed Test)
DefinitionLaboratory-Developed Test (LDT) — an assay developed and validated by an individual laboratory for in-house clinical use and regulated under CLIA as high-complexity testing; not FDA-approved but acceptable for clinical use.
RegulationLDTs are regulated by CMS under CLIA; FDA clearance/approval is not required for clinical use though some tests have FDA approval when submitted.
Clinical noteMany specialized infectious disease assays are LDTs and must be validated by the performing laboratory prior to clinical reporting.
CDC guidance documents referenced
CDC guidance — RMSF and rickettsial diseasesCDC clinical and laboratory guidance for Rocky Mountain Spotted Fever (diagnosis and testing) is cited and recommended as a primary reference for rickettsial testing approaches.
CDC guidance — ArbovirusesCDC clinical testing guidance for dengue and Zika (including NAAT, IgM, NS1, and infant/pregnancy-specific recommendations) is cited for timing and specimen selection.
CDC guidance — Malaria and BabesiosisCDC pages on malaria testing and babesiosis case definition/testing are cited for diagnostic standards (microscopy, NAAT, and serology use).
Professional society sources (AAP, ASM) referenced
American Academy of Pediatrics (AAP) Red BookAAP Red Book chapters (Babesiosis, Ehrlichia/Anaplasma, RMSF, dengue, chikungunya, etc.) are cited for pediatric diagnostic and testing recommendations.
American Society for Microbiology (ASM)ASM guidance (e.g., Zika testing updates) and IDSA/ASM joint laboratory diagnosis guidance are cited for specimen selection and assay performance considerations.
IDSA/ASM joint guidanceIDSA/ASM laboratory diagnosis recommendations for tickborne infections and malaria (including preferred specimens, PCR use, and microscopy guidance) are referenced.